Ligand sets October 29, 2026 results date for Ligand Pharmaceuticals stock

Published on 10/17/2026 at 19:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value was USD 5.9 billion. Ligand Pharmaceuticals stock was EUR 263.00 on October 16, 2026, down 0.38 percent versus Tradegate close.

Results date and valuation

Ligand Pharmaceuticals will publish third-quarter results on October 29, 2026.
Ligand's market capitalization was USD 5.9 billion on October 16, 2026.
Ligand Pharmaceuticals stock was EUR 263.00 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST, down 0.38 percent versus the Tradegate close.
Ligand Pharmaceuticals had a price-to-earnings ratio of 31.61 on October 16, 2026.

LGND, US53220K5048, Illustration mit AI erstellt.

Ligand Pharmaceuticals has set October 29, 2026 as the date for its third-quarter results. The company said in a release dated October 15, 2026 that it will publish the figures and hold a conference call at 8:30 a.m. Eastern time, according to Ligand Pharmaceuticals. Ligand Pharmaceuticals stock was EUR 263.00 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST, down 0.38 percent versus the Tradegate close of EUR 264.00 on October 16, 2026.

Market value reaches USD 5.9 billion

The company had a market capitalization of USD 5.9 billion on October 16, 2026. Its latest U.S. quote was USD 295.54 on Nasdaq at 4:00 p.m. ET on the same date, giving investors a separate view of the primary-market listing.

Ligand operates as a royalty aggregator for biopharmaceutical programs and also licenses Captisol and NITRICIL technologies. The company said its portfolio includes economic interests in more than 200 development and commercial-stage assets in the October 15, 2026 release.

Stock stays below its yearly high

The Nasdaq quote stood within a USD 175.89 to USD 326.63 52-week range on October 16, 2026. The USD 295.54 price was USD 31.09 below the high, equal to 9.52 percent below that level. Trading volume reached 164,503 shares against an average of 249,845 shares.

Valuation and the next date

Ligand carried a price-to-earnings ratio of 31.61 on October 16, 2026. The October 29 results date is the next scheduled company event, and the call is set to include a general business update. For investors, that date provides the next defined checkpoint for royalty income, pipeline progress and the company outlook.

Comparison with peers

Ligand Pharmaceuticals (Nasdaq, USD): minus 0.99 percent, P/E 31.61, market capitalization USD 5.9 billion

Royalty Pharma (Nasdaq, USD): plus 2.25 percent, P/E 35.03, market capitalization USD 27.1 billion

XOMA Royalty (Nasdaq, USD): P/E 25.59, market capitalization USD 710.2 million

Trading status in Germany

Ligand Pharmaceuticals had last stood at EUR 263.00 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST. The euro quotation was 0.38 percent below the Tradegate close of EUR 264.00 dated October 16, 2026.

The further course of trading is shown by the continuously updated real-time quote of Ligand Pharmaceuticals stock.